Placebo In Chronic Back Pain (Phase 2)

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Chronic Low Back Pain
Interventions
DRUG

Naproxen

Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.

DRUG

Omeprazole

Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.

DRUG

Placebo

Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.

Trial Locations (1)

60611

Northwestern University Feinberg School of Medicine, Chicago

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Apkar Apkarian

OTHER

NCT02986334 - Placebo In Chronic Back Pain (Phase 2) | Biotech Hunter | Biotech Hunter